2 Healthcare Stocks to Buy After Crushing Q3 Earnings Expectations: ELV & ISRG

Impact · against what's priced in

The Q3 results for ELV and ISRG provide positive operational data but do not trigger a valuation re-rating because they align with existing growth trajectories or fail to reverse the structural margin concerns the market has already priced in. ELV's expense ratio improvement is a step toward recovery, but ISRG's results merely confirm the guided growth range the market already accepts.

ELV+0.30

Challenges what's priced in

The price assumes